Last reviewed · How we verify
NCT06075212
Immune Reconstitution After Allo-HSCT and Blinatumomab
trial testing blinatumomab in Leukemia, Lymphoid in 20 participants. Status unknown.
30 September 2024
Quick facts
| Lead sponsor | Sichuan University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 1 October 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
Drugs / interventions tested
- blinatumomab (blinatumomab) — full drug profile →
Conditions studied
- Leukemia, Lymphoid — all drugs for Leukemia, Lymphoid →
Sponsor
Sichuan University
Who can join
Adults 16 to 65, any sex, with Leukemia, Lymphoid. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observation study is to test in relapsed or refractory acute lymphoblastic leukemia (R/R ALL) patients undergoing allogeneic hemopoietic stem-cell transplantation (allo-HSCT). The main question it aims to answer is: • Effect of post-transplant blinatumomab treatment on immune reconstitution after transplantation. Participants will undergo immune repertoire sequencing(IR-SEQ) before blinatumomab treatment, 6 months and 1 year after transplantation. Researchers will compare patients who don't receive blinatumomab treatment after transplantation to see if TCR or BCR expression differs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06075212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of blinatumomab
Trials testing the same drug.
- NCT06075238 — Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCT · Phase 2 · not yet recruiting
- NCT06111625 — Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL · Phase 2 · recruiting
- NCT04044560 — Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant · Phase 2 · terminated
- NCT03523429 — PETHEMA-BLIN-01/PET069014 (BLIN-01) · Phase 2 · terminated
- NCT02961881 — A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab · Phase 1 · completed
Other recruiting trials for Leukemia, Lymphoid
Currently open trials in the same condition.
- NCT06516679 — Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia · Phase 2 · recruiting
- NCT06111625 — Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL · Phase 2 · recruiting
Other Sichuan University trials
Trials by the same sponsor.
- NCT07501169 — Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lun · Phase 2 · not yet recruiting
- NCT07362732 — Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07374250 — Perioperative Ivonescimab Plus S-1 and Oxaliplatin (SOX) for Locally Advanced Gastric or GEJ Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07332663 — Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection · EARLY_PHASE1 · not yet recruiting
- NCT07258147 — Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06075212 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sichuan University
- Last refreshed: 10 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06075212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing